What are Cognizant's strategies for adapting to the changing business environment?

Even in the era of expanded newborn screening, utility of cord blood thyroid stimulating hormone (cTSH) for diagnosis of congenital hypothyroidism (CH) ... Jan 16, 2019 ... The stock is not undergoing any short term correction. Share buybacks is keeping the bottom under check. Reduction in floating stock ( due to ... The Cognizant Technology's current Enterprise Value Over EBITDA is estimated to increase to 20.54. The Cognizant Technology's current Enterprise Value Multiple ... The intrinsic value of one CTSH stock under the Base Case scenario is 84.94 USD. Compared to the current market price of 72.9 USD, Cognizant Technology ... Latest Quarter | Q1 2025 · Press Release · Presentation · Infographic · Webcast · Transcript · Form 10-Q(opens in new window) · All Quarters Investor Toolkit ... The Element i+™ immunodiagnostic analyzer supports diagnostic needs with total T4, cortisol, progesterone, cTSH, cCRP, and the Nu.Q® cancer test. Jun 11, 2023 ... Cognizant is trading at its lowest PE multiple in many years, the company has been consistently growing cash flow, buying back shares, and they ... Jan 26, 2024 ... ... (CTSH) locus. In addition to genetics, environmental factors such as viral infections, pesticide exposure, and changes in the gut microbiome ... This study shows that the risk variant rs3825932 in the candidate gene cathepsin H (CTSH) predicts β-cell function in both model systems and human T1D, ... How much dividend does Cognizant Technology Solutions Corp pay? Within the last 12 months, Cognizant Technology Solutions Corp paid a dividend of $1.21. For the ...